Global Hospital-acquired Urinary Tract Infection Testing Market 2016-2020

Overview of the global hospital-acquired urinary tract infection testing market

Technavio’s market research analyst predicts the global hospital-acquired urinary tract infection testing market to grow at a CAGR of around 19% between 2016 and 2020. Urinary tract infection occupies the largest share in the HAIs category, and the number is constantly growing. This has encouraged several vendors to develop innovative testing products that will subsequently augment the demand for hospital-acquired urinary tract infection testing products. Several technological advancements have enhanced the testing procedures for urinary tract infection, as they are more precise, sensitive, generate faster outcomes, and provide a broader range of pathogen detection as compared with the most traditional methods. Moreover, the innovative techniques in bioinformatics and software programs help manage a massive amount of data and offer better-quality results from tests such as molecular diagnostics. These methods provide initiation of infection control practices, optimization of treatment selection, reduced hospital stay, and improved surveillance of infectious diseases. Also, hospitals are setting up infection control committees that focus on only HAIs. Such infection control committee is responsible for the evaluation and planning of evidence-based practice, resource allocation, and prioritization of matters related to infection control.

Geographically, the Americas dominated the market and accounted for the largest market share in 2015. The high prevalence of infectious diseases, leading to the increased demand for diagnostic products and services and focus on disease management has propelled market growth in this region. The US is the largest revenue contributor for the hospital-acquired UTI testing market in the Americas owing to the massive sales of infectious disease diagnostic products and urology devices. Moreover, factors like increased laboratory automation, the shift toward rapid POC diagnostic tests, and approval of new products by the Food and Drug Administration (FDA) will further boost the market’s growth in the coming years.

Competitive landscape and key vendors

The global hospital-acquired UTI testing device market is highly fragmented with the presence of large, medium, and small-sized companies. The key vendors in the market are forming partnerships and offering premium-priced products to sustain their market shares. However, the local vendors are selling products at lower prices, which is posing a serious threat to the large companies. The increasing prevalence of infectious diseases gives significant opportunities to the life science companies to focus on their R&D investments on devices for the efficient diagnosis of infectious diseases. Companies such as Siemens Healthineers, bioMerieux, Roche Diagnostics, and Beckman Coulter have expanded their product portfolio for diagnosis of most communicable diseases. Moreover, constant advances in technology, and innovative product launches will further increase the competition among vendors.